Table 2

Evaluation populations

PurposeBias and reliabilityExternal validity+
SourceTest-retest study
(n = 148)Greenbaum study
(n = 191)Rituximab treated
(n = 57)Rituximab placebo
(n = 30)
Age (years)*16.2 ± 618.1 ± 8.819.0 ± 8.617.3 ± 7.8
Sex (% female)39%38%37%40%
Race (% white)86%93%96%97%
Ethnicity (% Hispanic)7%7%5%10%
C-peptide 2-h AUC (pmol/mL)*
 Baseline0.49 ± 0.500.71 ± 0.340.77 ± 0.430.71 ± 0.37
 Follow-up
  <10 days0.46 ± 0.44
  6 months0.56 ± 0.390.79 ± 0.570.59 ± 0.51
  12 months0.43 ± 0.340.62 ± 0.420.45 ± 0.48
  24 months0.36 ± 0.370.47 ± 0.460.35 ± 0.42
  • *Mean ± SD.

  • +Both data sets are from the rituximab study. The C-peptide data reported here are only from subjects used in the intention-to-treat analysis. For baseline, mean and SD do not match the values reported in Table 1 of the rituximab study, which included all subjects.